<DOC>
	<DOCNO>NCT00282230</DOCNO>
	<brief_summary>A study evaluate safety efficacy Prograf/FK778 de novo kidney transplant patient</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Prograf/FK778 Prograf/MMF de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient recipient primary retransplanted cadaveric nonHLAidentical living donor kidney . Patient must receive first oral dose randomize study drug within 48 hour transplant procedure . Patient receive receive organ transplant kidney Patient receive kidney transplant cadaveric donor &gt; = 60 year age .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Malononitrilamide</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>treatment efficacy</keyword>
	<keyword>treatment outcome</keyword>
</DOC>